Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update

Posted by Francis Steltz on Sep 30th, 2026

Revelation Biosciences, Inc. (NASDAQ:REVB – Get Free Report) saw a large drop in short interest in the month of September. As of September 15th, there was short interest totaling 256 shares, a drop of 56.0% from the August 31st total of 582 shares. Based on an average trading volume of 14,833 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are short sold.

Revelation Biosciences Price Performance

Shares of NASDAQ:REVB traded up $0.01 during trading on Wednesday, hitting $0.82. 21,512 shares of the company’s stock were exchanged, compared to its average volume of 249,959. Revelation Biosciences has a 52-week low of $0.81 and a 52-week high of $6.76. The business’s 50-day simple moving average is $1.02 and its 200 day simple moving average is $1.07. The company has a market cap of $3.27 million, a price-to-earnings ratio of -0.07 and a beta of -0.14.

Revelation Biosciences (NASDAQ:REVB – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.01. On average, sell-side analysts anticipate that Revelation Biosciences will post -5.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Revelation Biosciences

An institutional investor recently raised its stake in Revelation Biosciences stock. Sabby Management LLC boosted its stake in shares of Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) by 192.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 605,702 shares of the company’s stock after acquiring an additional 398,651 shares during the period. Revelation Biosciences accounts for 0.7% of Sabby Management LLC’s portfolio, making the stock its 8th largest holding. Sabby Management LLC owned approximately 8.78% of Revelation Biosciences worth $484,000 as of its most recent filing with the SEC. 12.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday, August 25th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Read Our Latest Stock Report on REVB

Revelation Biosciences Company Profile

(Get Free Report)

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunologic therapies for diseases with significant unmet medical needs. The company’s research is centered on therapeutics designed to stimulate or modulate the body’s innate immune system, the first line of defense against infection and other disease processes.

Its development pipeline has included REVTx-99, an investigational intranasal therapy based on a proprietary beta-glucan formulation. The candidate has been studied for its potential to help prevent or reduce the severity of respiratory viral infections and associated complications, including acute respiratory distress.